Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Spesolimab in Korean Patients With Flares With Generalized Pustular Psoriasis

The primary and secondary objectives are to respectively monitor the safety and effectiveness of Spesolimab IV in Korean patients with flares with generalized pustular psoriasis (GPP) in a routine medical practice.

Inclusion criteria:

• Patients starting Spesolimab IV for the first time in accordance with the approved label in Korea (complete enumeration for the first 2 years after product launch)
• Patients with generalized pustular psoriasis (GPP) flare
• Age >/=19 years at enrolment
• Patients who have signed the data release consent form

Exclusion criteria:

• Patients with Severe or life-threatening hypersensitivity to Spesolimab or to any of the excipients
• Patients with clinically important active infections (e.g. active tuberculosis)